Experienced in Multicentric Castleman Disease (MCD)

Dr. Bart L. Scott

Oncology
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
27 Years of Experience
Experienced in Multicentric Castleman Disease (MCD)
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bart Scott is an Oncologist in Seattle, Washington. Dr. Scott has been practicing medicine for over 27 years and is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Leukemia, and Bone Marrow Aspiration. Dr. Scott is currently accepting new patients.

His clinical research consists of co-authoring 136 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
University Of Washington Medical Ctr
Languages Spoken
English
Arabic
Mandarin
Sindhi
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1959 Ne Pacific St, Seattle, WA 98195
Other Locations
THE ASSOCIATION OF UNIVERSITY PHYSICIANS
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Cedazuridine
Study Phase: Phase 2/Phase 3
A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Procedure, Drug
Study Drugs: Daunorubicin, Cytarabine
Study Phase: Phase 1
Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)
Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)
Enrollment Status: Completed
Publish Date: February 15, 2024
Intervention Type: Other, Drug
Study Drugs: Azacitidine, Decitabine
Study Phase: Phase 2
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 17, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
A Phase II Study of Deferasirox in Patients With Myelodysplastic Syndromes Who Are Anemic With Iron Overload
A Phase II Study of Deferasirox in Patients With Myelodysplastic Syndromes Who Are Anemic With Iron Overload
Enrollment Status: Terminated
Publish Date: July 01, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

136 Total Publications

Pre-Hematopoietic Cell Transplant Ruxolitinib in Transplant-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.
Pre-Hematopoietic Cell Transplant Ruxolitinib in Transplant-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.
Journal: Transplantation and cellular therapy
Published: July 21, 2025
Similar Doctors
Advanced in Multicentric Castleman Disease (MCD)
Dr. Kiarash Kojouri
Oncology | Hematology | Hematology Oncology
Advanced in Multicentric Castleman Disease (MCD)
Dr. Kiarash Kojouri
Oncology | Hematology | Hematology Oncology

Public Hospital Dist No 1 Skagit

307 S 13th St, Suite 100, 
Mount Vernon, WA 
 (53.2 miles away)
360-814-2146
Languages Spoken:
English, Castilian, Farsi, Hindi, Mandarin, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Kiarash Kojouri is an Oncologist and a Hematologist in Mount Vernon, Washington. Dr. Kojouri is rated as a Distinguished provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Paget Disease of the Breast, and Richter Syndrome. Dr. Kojouri is currently accepting new patients.

Experienced in Multicentric Castleman Disease (MCD)
Dr. Goldy Bansal
Oncology | Hematology
Experienced in Multicentric Castleman Disease (MCD)
Dr. Goldy Bansal
Oncology | Hematology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (1.9 miles away)
206-288-1000
Languages Spoken:
English, Arabic, Hindi, Portuguese, Punjabi, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Goldy Bansal is an Oncologist and a Hematologist in Seattle, Washington. Dr. Bansal is rated as an Advanced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). Her top areas of expertise are Essential Thrombocythemia, B-Cell Lymphoma, Breast Cancer, and Paget Disease of the Breast. Dr. Bansal is currently accepting new patients.

Advanced in Multicentric Castleman Disease (MCD)
Dr. Jaideep Shenoi
Hematology Oncology | Hematology | Oncology
Advanced in Multicentric Castleman Disease (MCD)
Dr. Jaideep Shenoi
Hematology Oncology | Hematology | Oncology

Public Hospital Dist No 1 Skagit

307 S 13th St, 
Mount Vernon, WA 
 (53.2 miles away)
Languages Spoken:
English, Hindi, Hungarian, Kannada, Konkani, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jaideep Shenoi is a Hematologist Oncology specialist and a Hematologist in Mount Vernon, Washington. Dr. Shenoi is rated as an Advanced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Pleuropulmonary Blastoma, Anemia, Familial Colorectal Cancer, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Shenoi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Scott's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile